Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
We recently reported that in rodent models of type 2 diabetes (T2D), a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces remission of hyperglycemia that is sustained for weeks. To clarify the peripheral mechanisms underlying this effect, we used the Zucker diabetic fatty fa/fa rat model of T2D, which, like human T2D, is characterized by progressive deterioration of pancreatic β-cell function after hyperglycemia onset. We report that although icv FGF1 injection delays the onset of β-cell dysfunction in these animals, it has no effect on either glucose-induced insulin secretion or insulin sensitivity. These observations suggest that FGF1 acts in the brain to stimulate insulin-independent glucose clearance. On the basis of our finding that icv FGF1 treatment increases hepatic glucokinase gene expression, we considered the possibility that increased hepatic glucose uptake (HGU) contributes to the insulin-independent glucose-lowering effect of icv FGF1. Consistent with this possibility, we report that icv FGF1 injection increases liver glucokinase activity by approximately twofold. We conclude that sustained remission of hyperglycemia induced by the central action of FGF1 involves both preservation of β-cell function and stimulation of HGU through increased hepatic glucokinase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670 · cited 1×
“Excess glucagon secretion also has been hypothesized to drive diabetic hyperglycemia (41), and plasma glucagon levels were signi fi cantly decreased in ZDF rats receiving icv FGF1 compared with icv Veh.”
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · cited 1×
“Although glucose lowering elicited by these peptides was initially hypothesized to involve actions primarily on peripheral tissues (19 – 21), subsequent work revealed that an action in the brain is suf fi cient (5,22 – 26) and may be necessary (27) for this effect.”
Leptin and the Central Nervous System Control of Glucose Metabolism
Morton, G. J., & Schwartz, M. W. (2011) · Physiological Reviews · doi:10.1152/physrev.00007.2010 · Cited by 338
Self-citationRole of Glucose Effectiveness in the Determination of Glucose Tolerance
Best, J. D., Kahn, S. E., Ader, M., Watanabe, R. M., Ni, T. C., & Bergman, R. N. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.1018 · Cited by 290
Self-citationLan, T., Morgan, D. A., Rahmouni, K., Sonoda, J., Fu, X., Burgess, S. C., Holland, W. L., Kliewer, S. A., & Mangelsdorf, D. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.005 · Cited by 261 · cited 1×
“Although glucose lowering elicited by these peptides was initially hypothesized to involve actions primarily on peripheral tissues (19–21), subsequent work revealed that an action in the brain is sufficient (5,22–26) and may be necessary (27) for this effect.”
BackgroundNeural connections between the hypothalamus and the liver
Uyama, N., Geerts, A., & Reynaert, H. (2004) · The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology · doi:10.1002/ar.a.20086 · Cited by 201 · cited 1×
“With respect to the mechanism whereby FGF1 action in the brain induces liver GCK gene expression and enzyme activity, we note that after icv FGF1 injection, cellular activation is concentrated in the mediobasal hypothalamus (1), and sympathetic connections have been identified between this brain area and liver (44).”
Ryan, K. K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S. G., Woods, S. C., & Seeley, R. J. (2013) · Endocrinology · doi:10.1210/en.2012-1891 · Cited by 185
Cited by
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Alonge, K. M., Mirzadeh, Z., Scarlett, J. M., Logsdon, A. F., Brown, J. M., Cabrales, E., Chan, C. K., Kaiyala, K. J., Bentsen, M. A., Banks, W. A., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00275-6 · Cited by 63
“Population characteristics Brain specimens were collected from 5 patients (age/sex/PMI/diagnosis): (1) 23y/F/8h/cervical spinal cord glioma, (2) 56y/F/10h/ temporal lobe glioblastoma, (3) 59y/M/13h/severe traumatic brain injury, (4) 63y/M/4h/occipital lobe glioblastoma, (5) 65y/ F/18h/frontal lobe hemorrhagic stroke.”
MethodResultSelf-citation
Metadata
- Authors
- Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N. K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., Stefanovski, D., Bergman, R. N., Piccinini, F., Kaiyala, K. J., Shiota, M., Morton, G. J., & Schwartz, M. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-12-06
- Volume
- 68
- Issue
- 3
- Pages
- 654-664
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2902206070
- Cited by
- 50
- References
- 16
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain. https://app.cochat.ai/papers/10.2337/db18-0498
- The paper
- Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N. K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., Stefanovski, D., Bergman, R. N., Piccinini, F., Kaiyala, K. J., Shiota, M., Morton, G. J., & Schwartz, M. W. (2019). Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain. Diabetes. https://doi.org/10.2337/db18-0498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.